Patents
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
02/2013
02/28/2013WO2012145509A3 Adeno-associated-virus rep sequences, vectors, and viruses
02/28/2013WO2012142434A3 Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
02/28/2013WO2012139068A9 Co-administration of arsenic compounds and anti-herpes virus anti-virals
02/28/2013WO2012127379A3 A method for the analysis of the evolution of gene sequences and for the forecast of an emerging viral strain
02/28/2013WO2012125525A3 Equine rhinitis vaccine
02/28/2013WO2012007728A8 Method for producing toxoids using alpha - dicarbonyl compounds
02/28/2013WO2007025388A9 Anti-apoptotic protein antibodies
02/28/2013US20130052667 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
02/28/2013US20130052237 Methods of Manufacturing Viscous Liquid Pharmaceutical Formulations
02/28/2013US20130052235 Herpes simplex virus nanoemulsion vaccine
02/28/2013US20130052230 Salmonella vaccine
02/28/2013US20130052229 Compounds and methods for diagnosis and immunotherapy of tuberculosis
02/28/2013US20130052228 Attenuated fish vaccine following culture in iron limited media
02/28/2013US20130052227 Hyperblebbing shigella strains
02/28/2013US20130052226 Compositions and methods for preventing or treating a human parvovirus infection
02/28/2013US20130052225 Infectious dna vaccines against chikungunya virus
02/28/2013US20130052224 Production of poliovirus at high titers for vaccine production
02/28/2013US20130052223 Universal vaccine against h5n1 lineages
02/28/2013US20130052222 Influenza nucleic acid molecules and vaccines made therefrom
02/28/2013US20130052221 Dna-protein vaccination protocols
02/28/2013US20130052220 Yeast-hiv antigen compositions and methods of using the same
02/28/2013US20130052219 Preparation method of virus expressing alpha-galactose epitope and vaccine
02/28/2013US20130052218 Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
02/28/2013US20130052217 Tumor vaccination involving a humoral immune response against self-proteins
02/28/2013US20130052216 Targeted heterologous antigen presentation on calicivirus virus-like particles
02/28/2013US20130052215 Tumor vaccine
02/28/2013US20130052214 Identification of a peptide(s) that induces autoimmune anterior uveitis
02/28/2013US20130052213 Novel immunomodulatory peptide
02/28/2013US20130052212 Method for allogeneic cell therapy
02/28/2013US20130052211 Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
02/28/2013US20130052210 Use of ccl1 in therapy
02/28/2013US20130052209 Protein drug formulations and packages
02/28/2013US20130052208 Process for Preparing an Immunoglobulin Composition
02/28/2013US20130052207 Prognostic Method for Pulmonary Adenocarcinoma, Pulmonary Adenocarcinoma Detection Kit, and Pharmaceutical Composition for Treating Pulmonary Adenocarcinoma
02/28/2013US20130052206 Prognostic Marker For Cryoglobulinemic Vasculitis And B Cell Malignancies In HCV Infected Patients
02/28/2013US20130052205 Flt3 receptor antagonists for the treatment or the prevention of pain disorders
02/28/2013US20130052204 (poly)-glycerolphosphate-based anti-gram positive bacterial vaccine
02/28/2013US20130052203 In vivo screening models for treatment of qc-related disorders
02/28/2013US20130052202 HIGH AFFINITY, ANTI-HUMAN IgE ANTIBODIES
02/28/2013US20130052201 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
02/28/2013US20130052200 Naturally occurring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
02/28/2013US20130052199 Molecular Determinants of Myeloma Bone Disease and Uses Thereof
02/28/2013US20130052198 Anti-inflammatory factors
02/28/2013US20130052197 Novel anti-cd98 antibody and use thereof
02/28/2013US20130052196 Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
02/28/2013US20130052195 Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
02/28/2013US20130052194 Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
02/28/2013US20130052193 CONTROLLING ALLERGY AND ASTHMA BY ACTIVATING HUMAN DCs VIA DECTIN-1 OR TOLL-LIKE RECEPTOR 2 (TLR2)
02/28/2013US20130052192 Activatable Constructs
02/28/2013US20130052191 Anti-alpha2 integrin antibodies and their uses
02/28/2013US20130052190 CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
02/28/2013US20130052189 Method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
02/28/2013US20130052188 Systems and methods for obtaining immunoglobulin from blood
02/28/2013US20130052187 Antibodies Directed Against Hepatitis C Virus E1E2 Complex, Compositions of HCV Particles, and Pharmaceutical Compositions
02/28/2013US20130052186 Plasma Carboxypeptidase B as a Predictor for Disease Severity and Response
02/28/2013US20130052163 Human Rhinovirus (HRV) Antibodies
02/28/2013US20130052159 Methods for treatment of microbial disorders
02/28/2013US20130052135 Molecules With Extended Half-Lives, Compositions And Uses Thereof
02/28/2013US20130052131 Nanoparticles, methods of making nanoparticles, and methods of use
02/28/2013US20130052128 Upar Binding Agents and Methods of Use Thereof
02/28/2013US20130052127 Composite body for antigen or drug delivery
02/28/2013DE102010039018B4 Anti-La Antikörper und ihre Anwendung zum Immunotargeting Anti-La antibodies and their application to Immunotargeting
02/28/2013CA2846251A1 Anti-vcam-1 nanobodies
02/28/2013CA2845946A1 Fn14-binding proteins and uses thereof
02/28/2013CA2845884A1 Clostridium difficile antibodies
02/28/2013CA2845872A1 Herpes simplex virus nanoemulsion vaccine
02/28/2013CA2845810A1 Anti-ox40 antibodies and methods of using the same
02/28/2013CA2844543A1 Microorganisms carrying a tumor antigen
02/28/2013CA2844540A1 Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
02/28/2013CA2844538A1 Bispecific antigen binding molecules
02/28/2013CA2844306A1 Anti-tie2 antibodies and uses thereof
02/28/2013CA2837975A1 Bispecific t cell activating antigen binding molecules
02/27/2013EP2562188A2 Compositions and methods for diagnosing and treating cancer
02/27/2013EP2562187A1 Anti-CD37 antibodies
02/27/2013EP2562186A1 Antigen binding proteins that bind PAR-2
02/27/2013EP2562184A1 Novel immunogenic epitopes for immunotherapy
02/27/2013EP2562183A1 Novel immunogenic epitopes for immunotherapy
02/27/2013EP2562182A1 Novel immunogenic epitopes for immunotherapy
02/27/2013EP2561890A1 A method for producing medicaments for combatting tumors
02/27/2013EP2561885A2 Use of hades as tumor suppressor target
02/27/2013EP2561063A1 A vaccine comprising inactivated cells of haemophilus parasuis bacteria of serotype 5
02/27/2013EP2560994A2 Antibodies to cd122
02/27/2013EP2560990A1 Novel allergen
02/27/2013EP2560989A1 Cancer-related glycopeptide epitopes, antibodies and methods of use
02/27/2013EP2560691A2 Process for preparing an immunoglobulin composition
02/27/2013EP2560685A2 Methods and materials for reducing liver fibrosis
02/27/2013EP2560684A1 Fibronectin type iii domain-based multimeric scaffolds
02/27/2013EP2560683A2 Production of heteromultimeric proteins
02/27/2013EP2560682A2 Antibody preparations
02/27/2013EP2560681A1 Use of tau to monitor immunotherapy
02/27/2013EP2560680A2 Chimpanzee adenoviral vector-based filovirus vaccines
02/27/2013EP2560679A1 Eczema treatment
02/27/2013EP2560678A1 Pharmaceutical compositions
02/27/2013EP2560677A1 Cold treatment
02/27/2013EP2560674A2 Nanoparticle targeting to ischemia for imaging and therapy
02/27/2013EP2560658A2 Methods of enhancing antibody-dependent cellular cytotoxicity
02/27/2013EP2560641A2 Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
02/27/2013CN102947446A Prognostic method for pulmonary adenocarcinoma, pulmonary adenocarcinoma detection kit, and pharmaceutical composition for treating pulmonary adenocarcinoma
02/27/2013CN102947338A Neutralizing prolactin receptor antibodies and their therapeutic use
02/27/2013CN102947337A Methods for treating colorectal cancer